JohnSKauhMDFACP

Oncology • New Brunswick, NJ

Gastrointestinal Cancer, Hematologic Oncology

Chief Medical Officier Tvardi Therapeutics

Join to view full profile

Dr. Kauh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kauh's full profile

Already have an account?

Office
195 Little Albany Street
New Brunswick, NJ 08901
Phone+1 732-235-7066

Fax+1 732-235-8234

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 2000 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1997 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997

Certifications & Licensure

NJ State Medical License 2015 - 2025
GA State Medical License 2003 - 2017
DC State Medical License 2000 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 1
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies Start of enrollment: 2008 Apr 01
Completed
Phase 1
A Phase I Trial of Bortezomib and Sunitinib Start of enrollment: 2008 Feb 01
Completed
Phase 1
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2010 Sep 01
Completed
Phase 1
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Start of enrollment: 2017 Oct 25
Completed
Phase 1
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Start of enrollment: 2019 Sep 26
Active, not recruiting
Phase 1
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Start of enrollment: 2019 Aug 26
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

143 citations
Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
David A. Kooby, Vasili Egnatashvili, Swetha Srinivasan, Abbas Chamsuddin, Keith A. Delman
Journal of Vascular and Interventional Radiology. 2010-02-01
5881 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian
The New England Journal of Medicine. 2012-06-28
60 citations
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Anthony W. Tolcher, Jordan Berlin, Jan Cosaert, John S. Kauh, Emily Chan
Cancer Chemotherapy and Pharmacology. 2017-03-09

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Fellow